Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioAtla Highlights FDA Alignment On Phase 3 Ozuriftamab Vedotin Trial Design; Says Co Continues Preparations For Enabling Initiation Of Phase 3 Study; Co Maintains Previous Guidance

Author: Benzinga Newsdesk | September 08, 2025 07:07am
  • FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval
  • Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next year
  • Company maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year

Posted In: BCAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist